Literature DB >> 33422093

The EGFR-HSF1 axis accelerates the tumorigenesis of pancreatic cancer.

Weikun Qian1, Ke Chen1,2, Tao Qin1, Ying Xiao1, Jie Li1, Yangyang Yue1, Cancan Zhou1, Jiguang Ma3, Wanxing Duan1, Jianjun Lei1, Liang Han1, Li Li4, Xin Shen3, Zheng Wu1, Qingyong Ma5, Zheng Wang6.   

Abstract

BACKGROUND: Pancreatic ductal adenocarcinoma (PDAC) is one of the most malignant diseases because of its non-symptomatic tumorigenesis. We previous found heat shock factor 1 (HSF1) was critical for PDAC progression and the aim of this study was to clarified the mechanisms on early activation of HSF1 and its role in the pancreatic cancer tumorigenesis.
METHODS: The expression and location of HSF1 on human or mice pancreatic tissues were examined by immunohistochemically staining. We mainly used pancreatic acinar cell 3-dimensional (3D) culture and a spontaneous pancreatic precancerous lesion mouse model called LSL-KrasG12D/+; Pdx1-Cre (KC) (and pancreatitis models derived from KC mice) to explore the pro-tumorigenesis mechanisms of the HSF1 in vitro and in vivo. Bioinformatics and molecular experiments were used to explore the underlying mechanisms between HSF1 and epidermal growth factor receptor (EGFR).
RESULTS: In this study, we found that pharmacological inhibition of HSF1 slowed pancreatic cancer initiation and suppressed the pancreatitis-induced formation of pancreatic precancerous lesion. Next, bioinformatics analysis revealed the closely linked between HSF1 and EGFR pathway and we also confirmed their parallel activation in pancreatic precancerous lesions. Besides, the pharmacological inhibition of EGFR suppressed the initiation of pancreatic cancer and the activation of HSF1 in vivo. Indeed, we demonstrated that the EGFR activation that mediated pancreatic cancer tumorigenesis was partly HSF1-dependent in vitro.
CONCLUSION: Hence, we concluded that the EGFR-HSF1 axis promoted the initiation of pancreatic cancer.

Entities:  

Keywords:  Epidermal growth factor receptor; Heat shock factor 1; Pancreatic ductal adenocarcinoma; Transgenic mice; Tumorigenesis

Year:  2021        PMID: 33422093     DOI: 10.1186/s13046-020-01823-4

Source DB:  PubMed          Journal:  J Exp Clin Cancer Res        ISSN: 0392-9078


  56 in total

Review 1.  Targeting heat shock proteins in cancer.

Authors:  Gaëtan Jego; Adonis Hazoumé; Renaud Seigneuric; Carmen Garrido
Journal:  Cancer Lett       Date:  2010-11-13       Impact factor: 8.679

2.  Cancer statistics, 2019.

Authors:  Rebecca L Siegel; Kimberly D Miller; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2019-01-08       Impact factor: 508.702

3.  Genomic analyses identify molecular subtypes of pancreatic cancer.

Authors:  Peter Bailey; David K Chang; Katia Nones; Amber L Johns; Ann-Marie Patch; Marie-Claude Gingras; David K Miller; Angelika N Christ; Tim J C Bruxner; Michael C Quinn; Craig Nourse; L Charles Murtaugh; Ivon Harliwong; Senel Idrisoglu; Suzanne Manning; Ehsan Nourbakhsh; Shivangi Wani; Lynn Fink; Oliver Holmes; Venessa Chin; Matthew J Anderson; Stephen Kazakoff; Conrad Leonard; Felicity Newell; Nick Waddell; Scott Wood; Qinying Xu; Peter J Wilson; Nicole Cloonan; Karin S Kassahn; Darrin Taylor; Kelly Quek; Alan Robertson; Lorena Pantano; Laura Mincarelli; Luis N Sanchez; Lisa Evers; Jianmin Wu; Mark Pinese; Mark J Cowley; Marc D Jones; Emily K Colvin; Adnan M Nagrial; Emily S Humphrey; Lorraine A Chantrill; Amanda Mawson; Jeremy Humphris; Angela Chou; Marina Pajic; Christopher J Scarlett; Andreia V Pinho; Marc Giry-Laterriere; Ilse Rooman; Jaswinder S Samra; James G Kench; Jessica A Lovell; Neil D Merrett; Christopher W Toon; Krishna Epari; Nam Q Nguyen; Andrew Barbour; Nikolajs Zeps; Kim Moran-Jones; Nigel B Jamieson; Janet S Graham; Fraser Duthie; Karin Oien; Jane Hair; Robert Grützmann; Anirban Maitra; Christine A Iacobuzio-Donahue; Christopher L Wolfgang; Richard A Morgan; Rita T Lawlor; Vincenzo Corbo; Claudio Bassi; Borislav Rusev; Paola Capelli; Roberto Salvia; Giampaolo Tortora; Debabrata Mukhopadhyay; Gloria M Petersen; Donna M Munzy; William E Fisher; Saadia A Karim; James R Eshleman; Ralph H Hruban; Christian Pilarsky; Jennifer P Morton; Owen J Sansom; Aldo Scarpa; Elizabeth A Musgrove; Ulla-Maja Hagbo Bailey; Oliver Hofmann; Robert L Sutherland; David A Wheeler; Anthony J Gill; Richard A Gibbs; John V Pearson; Nicola Waddell; Andrew V Biankin; Sean M Grimmond
Journal:  Nature       Date:  2016-02-24       Impact factor: 49.962

Review 4.  The Chemical Biology of Molecular Chaperones--Implications for Modulation of Proteostasis.

Authors:  Kristoffer R Brandvold; Richard I Morimoto
Journal:  J Mol Biol       Date:  2015-05-21       Impact factor: 5.469

5.  Dual inhibition of the PI3K and MAPK pathways enhances nab-paclitaxel/gemcitabine chemotherapy response in preclinical models of pancreatic cancer.

Authors:  Niranjan Awasthi; David Kronenberger; Alexis Stefaniak; Md Sazzad Hassan; Urs von Holzen; Margaret A Schwarz; Roderich E Schwarz
Journal:  Cancer Lett       Date:  2019-05-30       Impact factor: 8.679

6.  EGF receptor signaling is essential for k-ras oncogene-driven pancreatic ductal adenocarcinoma.

Authors:  Carolina Navas; Isabel Hernández-Porras; Alberto J Schuhmacher; Maria Sibilia; Carmen Guerra; Mariano Barbacid
Journal:  Cancer Cell       Date:  2012-09-11       Impact factor: 31.743

7.  MEK guards proteome stability and inhibits tumor-suppressive amyloidogenesis via HSF1.

Authors:  Zijian Tang; Siyuan Dai; Yishu He; Rosalinda A Doty; Leonard D Shultz; Stephen Byers Sampson; Chengkai Dai
Journal:  Cell       Date:  2015-02-12       Impact factor: 41.582

Review 8.  HSF1 at a glance.

Authors:  Anniina Vihervaara; Lea Sistonen
Journal:  J Cell Sci       Date:  2014-01-15       Impact factor: 5.285

Review 9.  Pancreatic cancer.

Authors:  Terumi Kamisawa; Laura D Wood; Takao Itoi; Kyoichi Takaori
Journal:  Lancet       Date:  2016-01-30       Impact factor: 79.321

10.  HSF1 drives a transcriptional program distinct from heat shock to support highly malignant human cancers.

Authors:  Marc L Mendillo; Sandro Santagata; Martina Koeva; George W Bell; Rong Hu; Rulla M Tamimi; Ernest Fraenkel; Tan A Ince; Luke Whitesell; Susan Lindquist
Journal:  Cell       Date:  2012-08-03       Impact factor: 41.582

View more
  5 in total

1.  Integrating Network Pharmacology and Experimental Verification to Explore the Mechanism of Effect of Zuojin Pills in Pancreatic Cancer Treatment.

Authors:  Kunpeng Wang; Xiongying Miao; Fanhua Kong; Siqi Huang; Jinggang Mo; Chong Jin; Yanwen Zheng
Journal:  Drug Des Devel Ther       Date:  2021-09-04       Impact factor: 4.162

2.  Overexpression of Circular RNA circ_0013587 Reverses Erlotinib Resistance in Pancreatic Cancer Cells Through Regulating the miR-1227/E-Cadherin Pathway.

Authors:  Huiting Xu; Runzhi Chen; Qian Shen; Dongmei Yang; Hui Peng; Jin Tong; Qiang Fu
Journal:  Front Oncol       Date:  2021-09-06       Impact factor: 6.244

Review 3.  Extrachromosomal circular DNA: biogenesis, structure, functions and diseases.

Authors:  Ludi Yang; Ruobing Jia; Tongxin Ge; Shengfang Ge; Ai Zhuang; Peiwei Chai; Xianqun Fan
Journal:  Signal Transduct Target Ther       Date:  2022-10-02

4.  Circadian disruption enhances HSF1 signaling and tumorigenesis in Kras-driven lung cancer.

Authors:  Marie Pariollaud; Lara H Ibrahim; Emanuel Irizarry; Rebecca M Mello; Alanna B Chan; Brian J Altman; Reuben J Shaw; Michael J Bollong; R Luke Wiseman; Katja A Lamia
Journal:  Sci Adv       Date:  2022-09-28       Impact factor: 14.957

Review 5.  Proteasome regulators in pancreatic cancer.

Authors:  Nirosha J Murugan; Ioannis A Voutsadakis
Journal:  World J Gastrointest Oncol       Date:  2022-01-15
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.